# InvestorNewsBreaks – Intelligent Bio Solutions Inc. (NASDAQ: INBS) Strengthens FDA 510(k) Submission With New Security and Performance Data

Intelligent Bio Solutions (NASDAQ: INBS) announced the successful collection of new cybersecurity and performance data to support its upcoming FDA 510(k) resubmission for its Intelligent Fingerprinting Drug Screening System. The company conducted rigorous penetration and electromagnetic compatibility testing, along with advanced sweat quantification using ultra-micro balance technology, to validate system resilience and accuracy. With more than 6,000 hours of R&D effort and strategic guidance from FDA consultants, INBS aims to submit its updated findings in August as it targets U.S. market entry in 2025.

 To view the full press release, visit https://ibn.fm/vs3sB

 About Intelligent Bio Solutions Inc.

 Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the US include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

 NOTE TO INVESTORS: The latest news and updates relating to INBS are available in the company’s newsroom at https://ibn.fm/INBS

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-intelligent-bio-solutions-inc-nasdaq-inbs-strengthens-fda-510k-submission-with-new-security-and-performance-data/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/intelligent-bio-solutions-advances-drug-screening-tech-for-fda-resubmission/49e50dc6885266a30bab33ff05aeb714) 

 



[Reddit Post](https://www.reddit.com/r/HealthCareNewsInfo/comments/1m7h7yx/intelligent_bio_solutions_advances_drug_screening/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/257/23/fastFumP.webp)